Cargando…

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they...

Descripción completa

Detalles Bibliográficos
Autores principales: Korth, Johannes, Jahn, Michael, Dorsch, Oliver, Anastasiou, Olympia Evdoxia, Sorge-Hädicke, Burkhard, Eisenberger, Ute, Gäckler, Anja, Dittmer, Ulf, Witzke, Oliver, Wilde, Benjamin, Dolff, Sebastian, Kribben, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146144/
https://www.ncbi.nlm.nih.gov/pubmed/33923063
http://dx.doi.org/10.3390/v13050756
_version_ 1783697331009355776
author Korth, Johannes
Jahn, Michael
Dorsch, Oliver
Anastasiou, Olympia Evdoxia
Sorge-Hädicke, Burkhard
Eisenberger, Ute
Gäckler, Anja
Dittmer, Ulf
Witzke, Oliver
Wilde, Benjamin
Dolff, Sebastian
Kribben, Andreas
author_facet Korth, Johannes
Jahn, Michael
Dorsch, Oliver
Anastasiou, Olympia Evdoxia
Sorge-Hädicke, Burkhard
Eisenberger, Ute
Gäckler, Anja
Dittmer, Ulf
Witzke, Oliver
Wilde, Benjamin
Dolff, Sebastian
Kribben, Andreas
author_sort Korth, Johannes
collection PubMed
description The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination. We investigated the SARS-CoV-2 immune response via SARS-CoV-2 IgG detection in 23 renal transplant recipients after two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol. The antibody response was evaluated once with an anti-SARS-CoV-2 IgG CLIA 15.8 +/− 3.0 days after the second dose. As a control, SARS-CoV-2 IgG was determined in 23 healthcare workers (HCW) and compared to the patient cohort. Only 5 of 23 (22%) renal transplant recipients were tested positive for SARS-CoV-2 IgG antibodies after the second dose of vaccine. In contrast, all 23 (100%) HCWs were tested positive for antibodies after the second dose. Thus, the humoral response of renal transplant recipients after two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech, Kronach, Germany) is impaired and significantly lower compared to healthy controls (22% vs. 100%; p = 0.0001). Individual vaccination strategies might be beneficial in these vulnerable patients.
format Online
Article
Text
id pubmed-8146144
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81461442021-05-26 Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) Korth, Johannes Jahn, Michael Dorsch, Oliver Anastasiou, Olympia Evdoxia Sorge-Hädicke, Burkhard Eisenberger, Ute Gäckler, Anja Dittmer, Ulf Witzke, Oliver Wilde, Benjamin Dolff, Sebastian Kribben, Andreas Viruses Communication The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination. We investigated the SARS-CoV-2 immune response via SARS-CoV-2 IgG detection in 23 renal transplant recipients after two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol. The antibody response was evaluated once with an anti-SARS-CoV-2 IgG CLIA 15.8 +/− 3.0 days after the second dose. As a control, SARS-CoV-2 IgG was determined in 23 healthcare workers (HCW) and compared to the patient cohort. Only 5 of 23 (22%) renal transplant recipients were tested positive for SARS-CoV-2 IgG antibodies after the second dose of vaccine. In contrast, all 23 (100%) HCWs were tested positive for antibodies after the second dose. Thus, the humoral response of renal transplant recipients after two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech, Kronach, Germany) is impaired and significantly lower compared to healthy controls (22% vs. 100%; p = 0.0001). Individual vaccination strategies might be beneficial in these vulnerable patients. MDPI 2021-04-25 /pmc/articles/PMC8146144/ /pubmed/33923063 http://dx.doi.org/10.3390/v13050756 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Korth, Johannes
Jahn, Michael
Dorsch, Oliver
Anastasiou, Olympia Evdoxia
Sorge-Hädicke, Burkhard
Eisenberger, Ute
Gäckler, Anja
Dittmer, Ulf
Witzke, Oliver
Wilde, Benjamin
Dolff, Sebastian
Kribben, Andreas
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
title Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
title_full Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
title_fullStr Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
title_full_unstemmed Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
title_short Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
title_sort impaired humoral response in renal transplant recipients to sars-cov-2 vaccination with bnt162b2 (pfizer-biontech)
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146144/
https://www.ncbi.nlm.nih.gov/pubmed/33923063
http://dx.doi.org/10.3390/v13050756
work_keys_str_mv AT korthjohannes impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT jahnmichael impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT dorscholiver impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT anastasiouolympiaevdoxia impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT sorgehadickeburkhard impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT eisenbergerute impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT gackleranja impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT dittmerulf impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT witzkeoliver impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT wildebenjamin impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT dolffsebastian impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech
AT kribbenandreas impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech